Regentis Biomaterials LTD. is a US-listed company in the health care equipment industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
Not valued: the figures our models need are missing or failed our data-quality checks.
Price vs value
No model value: limited reported history: available models are shown without a Buy/Hold/Sell rating. How we value companies.
Regentis Biomaterials LTD. valuation: adjust assumptions and compare models →
The Fundamentalytics view
Current signal Share count shrinking (buybacks): Diluted shares outstanding fell 79.5% year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
- Shrinking share count. Diluted shares fell 79.5% in a year, so each share owns more of the business.
Things to watch
No figure in Regentis Biomaterials LTD.'s latest results trips our warning thresholds.
Price chart
- 1 day0.0%
- 1 week+8.7%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-24.08
Growth
- Share count change
- −79.5%
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for RGNT from the sources we follow. See filings →
Valuation models
We value Regentis Biomaterials LTD. as an operating company, with every model that fits that kind of business. Cost of equity 9.5%: the 10-year Treasury yield (4.9%) plus a beta of 1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no positive revenue in the latest twelve months |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Regentis Biomaterials LTD. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.
Forecasts and guidance
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.68 | — | — | — |
Positioning
- Short interest
- 0.2% of tradable shares
- Days to cover
- 0.19 at average volume
- Short interest, 1 month
- +87% to October 15, 2026
- Held by institutions
- 25% of shares
- Held by insiders
- 14.0% of shares
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial health
- Short-term assets cover short-term liabilities The company doesn't report a short-term split. Not assessable.
- Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Operating income of −$7m against $79,000 of interest.
Dividends, buybacks and capital spending
- Diluted share count
- −79.5%
- year over year
Who owns it
- Reported value
- $3M
- Institutions reporting
- 6
- Shares held vs prior quarter
- ▲ 53.3%
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | $2.5M | 702K | 83.0% | ▲ 179.0% |
| Warberg Asset Management LLC | $306,170 | 87K | 10.3% | New |
| Jane Street Group, LLC | $152,966 | 43K | 5.1% | New |
| Renaissance Technologies LLC | $47,118 | 13K | 1.6% | New |
| UBS Group AG | $1,532 | 0K | 0.1% | ▲ 29.9% |
| Tower Research Capital LLC (TRC) | $39 | 0K | 0.0% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Regentis Biomaterials LTD.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chartFrom insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Recent SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Regentis Biomaterials LTD. in brief
- What does Regentis Biomaterials LTD. do?
- Regentis Biomaterials LTD. is a US-listed company in the health care equipment industry. Its financial year ends in December.
- What is Regentis Biomaterials LTD.'s stock ticker?
- Regentis Biomaterials LTD. trades under the ticker RGNT on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Regentis Biomaterials LTD.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Rosalind Advisors, Inc., Warberg Asset Management LLC and Jane Street Group, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Follow research on Regentis Biomaterials LTD.
New research on the companies we cover arrives in the weekly email. Free, one email a week.